Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Marubeni | 2.77% | $738.09K | $62.49B | 140.86% | 70 Outperform | |
| Banco Santander SA | 2.68% | $715.79K | $184.95B | 111.44% | 72 Outperform | |
| Barclays | 2.61% | $696.75K | $90.09B | 71.21% | 77 Outperform | |
| Mitsubishi UFJ | 2.58% | $688.33K | $212.77B | 53.16% | 77 Outperform | |
| Aercap Holdings | 2.45% | $654.01K | $25.84B | 48.88% | 77 Outperform | |
| Novartis | 2.44% | $650.76K | $312.45B | 48.76% | 80 Outperform | |
| ING Groep | 2.29% | $609.72K | $82.64B | 74.06% | 72 Outperform | |
| TSMC | 2.17% | $579.15K | $1.57T | 86.91% | 81 Outperform | |
| Teva Pharmaceutical | 2.09% | $558.45K | $39.61B | 104.42% | 63 Neutral | |
| NatWest Group | 2.09% | $557.83K | $67.48B | 47.68% | 81 Outperform |